

Ajanta Pharma Limited Ajanta Tower, 54-A, M V Road, Chakala, Andheri (E), Mumbai – 400 093, India

T +91 22 6060 9000 E legal.info@ajantapharma.com W www.ajantapharma.com



24th October 2025

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Scrip Code: BSE – AJANTPHARM 532331

Scrip Code: NSE AJANTPHARM EQ

Ref.: Intimation under Regulation 29(1)(e) and 42 of the Listing Regulations

Subject: Notice of the meeting of Board of Directors to consider dividend on equity shares of the company

Dear Sirs/Madam,

This is with reference to our letter dated 8th October 2025, informing you about the Board meeting scheduled on Monday, 3rd November 2025 to *inter-alia* consider and take on record the unaudited financial results for the second quarter and half year ended 30th September 2025.

Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider:

- a. declaration of 1st interim dividend for the financial year ending 31st March 2026; and
- b. fixation of Monday, 10th November 2025 as the Record Date for the payment of interim dividend, if declared.

You are requested to please take a note of the same and disseminate to all concerned.

Thanking you,

Yours faithfully,

Gaurang Shah

Sr. VP – Legal & Company Secretary